- Home
- POAI
POAI
Predictive Oncology Inc.
as 03-28-2025 4:00pm EST
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | PITTSBURGH |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 8.1M |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.55 - $3.06 | Next Earning Date: | 05-13-2025 |
| Revenue: | $1,484,223 | Revenue Growth: | -11.21% |
| Revenue Growth (this year): | -20.12% | Revenue Growth (next year): | 569.48% |
Latest Predictive Oncology Inc. News
POAI Breaking Stock News: Dive into POAI Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
Predictive Oncology (POAI) Uses AI to Slash Drug Discovery Timelines & Boost Cancer Research
GlobeNewswire
6 days ago
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
GlobeNewswire
11 days ago
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries
GlobeNewswire
a month ago
Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology
GlobeNewswire
a month ago
Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences
GlobeNewswire
a month ago
Predictive Oncology Closes Registered Direct Offering
GlobeNewswire
a month ago
Predictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire
a month ago
Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing
Compare POAI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "POAI Predictive Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.